Bottom line
IBB vs RYOIX: the short answer
IBB (iShares Biotechnology ETF) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 55% by weight.
But IBB is far broader, holding 254 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
IBB is cheaper at 0.44% vs 1.38% — a difference of $94 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs +2.5% for IBB.
Updated Nov 19, 2026
IBB vs RYOIX side by side
| IBB | RYOIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 1.38% |
| Annual cost per $10k | $44 | $138 |
| 10-yr cost on $10k (prospectus) | $555 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +28.0% | +30.7% |
| 5-yr return (annualized) | +2.5% | +4.0% |
| 10-yr return (annualized) | +4.4% | +5.9% |
| Best quarter | +26.8% | +28.3% |
| Worst quarter | −22.9% | −22.5% |
| Net assets (fund) | $5.9B | $136.8M |
| Number of holdings | 254 | 74 |
| Portfolio turnover | 27% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | RYOIX | Difference |
|---|---|---|---|
| 2025 | +28.0% | +30.7% | −2.7% |
| 2024 | −2.4% | −0.7% | −1.7% |
| 2023 | +3.6% | +6.1% | −2.4% |
| 2022 | −13.6% | −13.1% | −0.5% |
| 2021 | +1.0% | +1.8% | −0.8% |
| 2020 | +25.9% | +22.1% | +3.8% |
| 2019 | +24.8% | +25.0% | −0.3% |
| 2018 | −9.1% | −9.0% | −0.2% |
| 2017 | +21.2% | +29.7% | −8.5% |
| 2016 | −21.5% | −19.5% | −2.0% |
Source: Fund prospectus bar charts
Holdings overlap
16 of IBB's top 25 holdings also appear in RYOIX's top 25.
| Holding | IBB | RYOIX |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 4.32% |
| Gilead Sciences, Inc. | 7.52% | 4.49% |
| Amgen, Inc. | 7.50% | 5.05% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 2.93% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 2.36% |
| Argenx SE | 3.15% | 1.48% |
| Insmed, Inc. | 2.95% | 1.79% |
| Natera, Inc. | 2.11% | 2.12% |
| BeOne Medicines Ltd. | 2.11% | 2.17% |
| Biogen, Inc. | 2.03% | 2.13% |
| United Therapeutics Corp. | 1.82% | 1.72% |
| Incyte Corp. | 1.62% | 1.62% |
| Illumina, Inc. | 1.41% | 1.94% |
| Neurocrine Biosciences, Inc. | 1.34% | 1.52% |
| Ionis Pharmaceuticals, Inc. | 1.03% | 1.35% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between IBB and RYOIX?
Which is cheaper, IBB or RYOIX?
Should I own both IBB and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.